Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024
COPENHAGEN, Denmark, June 03, 2024 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ:EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, reported data from its ongoing Phase 2 study at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024. The data demonstrated vaccine-induced immune response in metastatic melanoma patients treated with the Company’s AI-Immunology™ designed personalized cancer vaccine, EVX-01, in combination with an anti-PD1 inhibitor. The EVX-01 vaccine targets neoantigens – antigenic sequences derived from cancer mutations – that are displayed on the surface of the cancer cells, allowing the immune system to recognize, attack and eliminate the malignant cells.